Lydus Medical

growth-positive

Lydus Medical has announced that its Vesseal device has received FDA 510(k) clearance. The Vesseal is a microvascular anastomosis suture deployment system designed to simplify and improve the consistency of microvascular surgeries. This device addresses the challenges of manual microanastomoses, which are complex and require significant skill and time. The FDA clearance is a significant milestone for Lydus Medical, as it allows the company to address unmet clinical needs in various surgical fields, including breast reconstruction and vascular access for haemodialysis. The Vesseal is expected to enhance surgical outcomes and improve patient care by providing a standardized approach to microvascular anastomosis.

growth-positive

Lydus Medical, a portfolio company of Sanara Ventures, has announced $2.7 million in Pre-A funding. The funding will support the companys ability to accelerate FDA clearance, scale product development, and prepare for market entry. Lydus Medical has developed a unique surgical device called Vesseal, which enables precise and rapid connection of blood and lymph vessels. The device aims to improve clinical outcomes, shorten operation time, and enable successful microsurgery procedures. The funding round was led by a leading US-based strategic player, with the participation of Sanara Ventures and existing shareholders. The investors include Sanara Ventures, Mor Research, Technion, Leon Recanatis private equity investment company, and Glenrock. Lydus Medical was founded in 2017 and focuses on automating the creation of small blood vessel anastomoses.